YOLFTbeta
BC

Bioceltix S.A.

BCX · WAR · Healthcare / Biotechnology

70.10PLN+4.40 (+6.70%)

Price History

Full chart

Market Stats

Previous Close65.70
Open66.00
Day Range65.60 – 72.00
52-Week Range70.00 – 102.40
Volume10.09K
Market Cap406.62M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.48
Dividend Yield0.00%
Beta0.91
50-Day Avg80.39
200-Day Avg82.70

About

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs. The company was founded in 2016 and is headquartered in Wroclaw, Poland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Lukasz Bzdzion
  • Employees46
  • Headquartersbud. III, Wroclaw, Poland, 51-317, Poland
  • Websitehttps://bioceltix.com

Leadership

  • Mr. Lukasz BzdzionCEO & President of the Management Board
  • Dr. Pawel Wielgus Eng., Ph.D.Member of the Management Board
  • Andrij WlachChief Financial Officer
  • Mr. Grzegorz OstropolskiChief Operating Officer
  • Mr. Lahoud ToumaDirector of Technology
  • Mr. Jakub WacekLegal Counsel & General Counsel
  • Dr. Patryk Reniewicz Ph.D.Head of R&D and Leader of the In Vitro Diagnostics Development Team
  • Ms. Agnieszka KielczykowskaHead of Procurement & Supply
  • Ms. Anna Olko-ChudyHead of the Management Office & Tissue Coordinator
  • Ms. Katarzyna WroblewskaHead of Quality Assurance

Financials

Income Statement

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue9.20K1.50K10.80K00000
Growth (%)--83.70%+620.00%-100.00%----
Cost of Revenue1.82M3.48M3.88M376.98K445.38K1.04M574.43K680.06K
Gross Profit-1.81M-3.48M-3.87M-376.98K-445.38K-1.04M-574.43K-680.06K
Gross Margin-19624.52%-232036.80%-35806.30%-----
Operating Expense114.14K295.91K121.86K5.84M9.23M14.78M18.26M16.64M
Operating Income-1.92M-3.78M-3.99M-6.21M-9.67M-15.82M-18.83M-17.32M
Operating Margin-20864.88%-251764.00%-36934.63%-----
EBITDA-754.48K-1.53M-2.13M-3.95M-8.49M-13.22M-14.04M-16.64M
EBITDA Margin-8198.69%-101800.53%-19683.87%-----
Net Income-775.69K-1.60M-2.35M-4.40M-8.92M-13.69M-14.90M-15.16M
Net Income Margin-8429.21%-106422.47%-21747.72%-----
R&D---1.93M1.28M3.84M6.36M3.50M
Interest Expense7.25K20.94K17.02K22.95K31.51K33.65K254.18K208.88K
Interest Expense % of Total Revenue78.76%1395.73%157.59%-----

Balance Sheet

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.30M3.23M4.80M8.20M5.99M12.74M41.85M75.63M
Total Liabilities1.73M1.32M1.48M2.20M2.50M2.27M3.44M2.36M
Total Equity1.57M1.91M3.32M6.00M5.15M10.47M38.42M73.28M
Cash1.57M1.10M3.20M6.05M4.12M9.31M33.63M68.40M
Total Debt-165.00K104.17K530.83K293.94K175.06K823.92K314.90K
Net Debt-1.57M-936.98K-3.10M-5.52M-3.83M-9.14M-32.81M-68.09M

Cash Flow

Currency: PLN2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.79M-1.67M-1.51M-4.04M-7.91M-14.75M-17.74M-12.10M
Investing Cash Flow-523.20K-179.67K-13.91K134.06K-351.73K-458.35K-84.24K-1.97M
Financing Cash Flow1.50M1.38M3.63M6.76M6.32M20.40M42.14M48.84M
Capital Expenditure523.20K179.67K13.91K5.98K351.73K458.35K242.78K1.97M
Free Cash Flow-2.31M-1.85M-1.53M-4.05M-8.26M-15.21M-17.98M-14.07M
FCF to OCF129.28%110.76%100.92%100.15%104.45%103.11%101.37%116.28%

Earnings

Report DateDec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Nov 25, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------
EPS Actual-0.48-0.44-0.57-0.85-0.82-0.74-0.99-0.92-0.91-1.02-1.02-0.78-0.61-0.77-0.76-0.89-0.64-1.03-0.92
Surprise-------------------
Timing-----------After-hours-After-hours-----

Key Statistics & Ratios

Market Cap406.62M
Enterprise Value359.89M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1657.15
Price / Book6.33
EPS-3.48
Book Value12.22
Revenue (TTM)0
Gross Profit (TTM)-2.64M
EBITDA-16.45M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-33.35%
Return on Assets-19.46%
Shares Outstanding5.53M
Shares Float4.44M
Beta0.91
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%